Reply To: Traders Market Weekly: Algorithms, Jobs and Holiday Markets

#68182
Truman
Participant

SpringWorks Therapeutics (SWTX 22.65, +1.88, +9.1%): receives FDA Approval of OGSIVEO

argenx SE (ARGX 445.80, -49.91, -10.0%): reports topline results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia; Study did not meet primary or secondary endpoints